This product consists of a CRISPR/Cas9-edited polyclonal knockout cell population derived from K-562 cells, with targeted disruption of the EDC3 gene. EDC3 encodes a scaffold protein essential for mRNA decapping, and its knockout provides a valuable loss-of-function model for studying post-transcriptional gene regulation. The polyclonal nature of the edited pool preserves genetic heterogeneity, offering a robust system for functional genomics without the selection biases of clonal isolation.
The K-562 cell line, originating from a chronic myeloid leukemia patient in blast crisis, is a multipotent hematopoietic model capable of spontaneous differentiation into erythroid, granulocytic, and monocytic lineages. These suspension-adapted cells express the BCR-ABL1 fusion and are widely used in leukemia research, drug screening, and studies of hematopoietic differentiation.
EDC3 acts as a scaffold that stimulates the DCP1-DCP2 decapping enzyme complex, removing the 5′ cap from mRNA and targeting it for XRN1-mediated 5′-3′ degradation. It orchestrates P-body assembly through interactions with DCP1A, DCP2, DDX6, PATL1, and LSM14A. The decapping complex integrates with RNA surveillance pathways involving UPF1, and EDC3 preferentially affects transcripts with AU-rich elements or miRNA targets. Upstream regulation is largely uncharacterized but may respond to cellular stress cues.
In K-562 leukemia cells, EDC3 loss likely alters stability of mRNAs governing proliferation, apoptosis, and differentiation. Disrupted P-body dynamics may dysregulate oncogenes or tumor suppressors, linking mRNA decay to leukemogenesis. This model enables mechanistic dissection of post-transcriptional control in chronic myeloid leukemia and facilitates identification of vulnerabilities in the decapping pathway.
Key applications include transcriptome profiling via RNA-seq or RT-qPCR, protein validation by Western blotting, and phenotypic analysis using flow cytometry. Researchers can assess mRNA stability with transcription inhibitors, visualize P-body changes by immunofluorescence, and conduct differentiation assays to evaluate lineage commitment. The population supports drug target validation and high-throughput screening. For further information, please contact Ascent Research.
